Storia in 4 fonti

FDA approves Lisraya as first oral drug for dermatomyositis

The FDA has approved Lisraya for the treatment of dermatomyositis in adults, the agency announced in a press release. The approval makes brepocitinib (Lisraya, Priovant Therapeutics) the first oral drug indicated for dermatomyositis.

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

healio.comStai leggendo2 g fa

FDA approves Lisraya as first oral drug for dermatomyositis

originale

Timeline cronologica

giovedì 27 agosto 2026·medpagetoday.com
First Oral Option for Dermatomyositis Gets FDA Green Light
Brepocitinib significantly improved overall symptom status in a phase III trial
giovedì 27 agosto 2026·endpoints.news
Roivant’s road to a potential blockbuster begins with Lisraya FDA approval
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across indications.

FDA approves Lisraya as first oral drug for dermatomyositis

Confronto fonti

FDA approves Lisraya as first oral drug for dermatomyositis

Timeline cronologica

First Oral Option for Dermatomyositis Gets FDA Green Light

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

First Oral Option for Dermatomyositis Gets FDA Green Light

FDA green lights Priovant drug for rare skin disease

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

FDA approves Lisraya as first oral drug for dermatomyositis

FDA green lights Priovant drug for rare skin disease